SAT-725 Impact of Ozempic (Semaglutide) on Reducing Total Knee Replacement Procedures in Patients with Osteoarthritis

Abstract Disclosure: M. Ayman: None. S. Manikonda: None. Background: Osteoarthritis (OA) is a leading cause of disability worldwide, particularly affecting the knee joint. Total knee replacement (TKR) remains a common intervention for patients with advanced OA. Obesity: is a well-established risk factor for the development and progression of knee OA, as excess weight places additional stress on weight-bearing joints, exacerbating symptoms. Thus, weight loss is a primary therapeutic target for managing knee OA and reducing the need for surgical intervention. While weight loss is known to reduce symptoms of OA and delay or avoid the need for TKR, pharmacological interventions like Ozempic (semaglutide), a GLP-1 receptor agonist used for weight management, may offer a promising approach. This systematic review and meta-analysis aim to evaluate whether Ozempic: leads to significant reductions in TKR procedures in patients with osteoarthritis. Methods: We systematically reviewed studies evaluating the effects of Ozempic on weight loss and knee OA symptoms, particularly focusing on any association with reduced TKR requirements. Eligible studies were identified from databases including PubMed, Cochrane, and Scopus. Both randomized controlled trials (RCTs) and observational studies were included. Data on weight loss, OA symptoms, and TKR procedures were extracted and analyzed. Results: Of the 12 studies that met inclusion criteria, 8 were RCTs, and 4 were observational studies. Ozempic significantly reduced body weight in OA patients (mean weight loss of 10-18%) over periods ranging from 12 to 52 weeks. OA symptom scores, including pain and functional outcomes, improved in 75% of studies, with a 30-45% reduction in symptoms. The meta-analysis revealed a 25% reduction in the likelihood of TKR procedures in Ozempic-treated patients, compared to controls. Clinical Implications Given the substantial healthcare burden of OA and TKR surgeries, Ozempic: represents a promising pharmacologic intervention for reducing the need for surgical procedures in obese OA patients. The observed weight loss and symptom improvements could offer an alternative to surgery, improving patient outcomes and reducing healthcare costs Conclusion: Ozempic appears to be effective in reducing body weight and improving OA symptoms, potentially delaying or reducing the need for TKR in patients with OA. Further large-scale trials are needed to confirm these findings and assess the long-term benefits of Ozempic for OA management. Presentation: Saturday, July 12, 2025